Longitudinal blood microsampling and proteome monitoring facilitate timely intervention in experimental type 1 diabetes

Symptoms of immune-mediated diseases (IMIDs) typically appear after irreversible tissue damage, making early interventions based on pre-symptomatic indicators crucial. Current efforts to identify molecular markers of early disease lack the resolution, convenience and cost efficiency required to prev...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2024-11
Main Authors: Parajuli, Anirudra, Bendes, Annika, Byvald, Fabian, Stone, Virginia, Ringqvist, Emma E, Butrym, Marta, Angelis, Emmanouli, Kipper, Sophie, Bauer, Stefan, Roxhed, Niclas, Schwenk, Jochen, Flodstrom-Tullberg, Malin
Format: Article
Language:English
Subjects:
Blood
Diabetes
Diabetes mellitus (insulin dependent)
Disease
Medical treatment
Proteomes
Viruses
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Symptoms of immune-mediated diseases (IMIDs) typically appear after irreversible tissue damage, making early interventions based on pre-symptomatic indicators crucial. Current efforts to identify molecular markers of early disease lack the resolution, convenience and cost efficiency required to prevent irreversible tissue damage. Analyzing frequently self-collected samples, such as dried blood spots (DBS), could enable the earlier detection of diseases, identify disease-predictive markers and facilitate tailored interventions. To test this, we regularly microsampled a mouse model infected with a type 1-diabetes (T1D)-associated virus. This longitudinal DBS sample collection was analyzed for 92 circulating proteins, revealing transient molecular changes in virus-infected animals that would have been missed with less frequent sampling. Machine learning predicted infection status after day 2 post-infection with >90% accuracy, enabling well-timed treatment of virus-infected animals and diabetes prevention. Our study demonstrates the utility of frequent blood microsampling to monitor disease during the pre-symptomatic phase, allowing for timely interventions.Competing Interest StatementNR is a co-founder and shareholder of the microsampling companies Capitainer AB and Samplimy Medical AB, and an inventor of several patents on microsampling solutions. Unrelated to this work, JMS has received travel support from Olink AB, and via the institution, conducted contract research for Capitainer AB. All other authors declare they have no competing interests.
DOI:10.1101/2024.11.19.624292